Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
CEO Transition: Dr. Helen Tayton-Martin will become CEO on November 24, bringing significant biotech leadership experience; Birgitte Rono will return to CSO.
MSD Partnership: MSD (Merck) exercised its option on EVX-B3, marking the first AI-discovered vaccine candidate in-licensed by a major pharma and bringing in a $7.5 million fee.
Cash Runway: Cash runway now extended into the second half of 2027, supported by the MSD deal, warrant exercises, and EIB debt conversion.
R&D Milestones: Two-year Phase II data on EVX-01 melanoma vaccine showed a 75% response rate and strong sustained T cell activity; new EVX-04 AML vaccine added to pipeline.
AI Platform Upgrade: Automated vaccine design module launched, reducing development time and enabling potential external partnerships.
Future Revenue Potential: MSD deal could generate up to $592 million in future milestone payments.
Active Partnerships: Multiple partnership discussions underway across oncology, infectious disease, target discovery, and platform capabilities.
